2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

Antonis Fanouriakis, Myrto Kostopoulou, Alessia Alunno, Martin Aringer, Ingeborg Bajema, John N. Boletis, Ricard Cervera, Andrea Doria, Caroline Gordon, Marcello Govoni, Frédéric Houssiau, David Jayne, Marios Kouloumas, Annegret Kuhn, Janni L. Larsen, Kirsten Lerstrøm, Gabriella Moroni, Marta Mosca, Matthias Schneider, Josef S. Smolen & 8 others Elisabet Svenungsson, Vladimir Tesar, Angela Tincani, Anne Troldborg, Ronald Van Vollenhoven, Jörg Wenzel, George Bertsias, Dimitrios T. Boumpas

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of GC. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab (RTX) may be considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion.

Original languageEnglish
Pages (from-to)736-745
JournalAnnals of the Rheumatic Diseases
Volume78
Issue number6
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Systemic Lupus Erythematosus
Expert Testimony
Glucocorticoids
Hydroxychloroquine
Antiphospholipid Antibodies
Hematologic Diseases
Azathioprine
Prednisone
Methotrexate
Communicable Diseases
Cardiovascular Diseases
Refractory materials
Body Weight
Physicians
Kidney
Skin
Therapeutics

Keywords

  • lupus nephritis
  • systemic lupus erythematosus
  • treatment

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., ... Boumpas, D. T. (2019). 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 78(6), 736-745. https://doi.org/10.1136/annrheumdis-2019-215089

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. / Fanouriakis, Antonis; Kostopoulou, Myrto; Alunno, Alessia; Aringer, Martin; Bajema, Ingeborg; Boletis, John N.; Cervera, Ricard; Doria, Andrea; Gordon, Caroline; Govoni, Marcello; Houssiau, Frédéric; Jayne, David; Kouloumas, Marios; Kuhn, Annegret; Larsen, Janni L.; Lerstrøm, Kirsten; Moroni, Gabriella; Mosca, Marta; Schneider, Matthias; Smolen, Josef S.; Svenungsson, Elisabet; Tesar, Vladimir; Tincani, Angela; Troldborg, Anne; Van Vollenhoven, Ronald; Wenzel, Jörg; Bertsias, George; Boumpas, Dimitrios T.

In: Annals of the Rheumatic Diseases, Vol. 78, No. 6, 01.01.2019, p. 736-745.

Research output: Contribution to journalArticle

Fanouriakis, A, Kostopoulou, M, Alunno, A, Aringer, M, Bajema, I, Boletis, JN, Cervera, R, Doria, A, Gordon, C, Govoni, M, Houssiau, F, Jayne, D, Kouloumas, M, Kuhn, A, Larsen, JL, Lerstrøm, K, Moroni, G, Mosca, M, Schneider, M, Smolen, JS, Svenungsson, E, Tesar, V, Tincani, A, Troldborg, A, Van Vollenhoven, R, Wenzel, J, Bertsias, G & Boumpas, DT 2019, '2019 update of the EULAR recommendations for the management of systemic lupus erythematosus', Annals of the Rheumatic Diseases, vol. 78, no. 6, pp. 736-745. https://doi.org/10.1136/annrheumdis-2019-215089
Fanouriakis, Antonis ; Kostopoulou, Myrto ; Alunno, Alessia ; Aringer, Martin ; Bajema, Ingeborg ; Boletis, John N. ; Cervera, Ricard ; Doria, Andrea ; Gordon, Caroline ; Govoni, Marcello ; Houssiau, Frédéric ; Jayne, David ; Kouloumas, Marios ; Kuhn, Annegret ; Larsen, Janni L. ; Lerstrøm, Kirsten ; Moroni, Gabriella ; Mosca, Marta ; Schneider, Matthias ; Smolen, Josef S. ; Svenungsson, Elisabet ; Tesar, Vladimir ; Tincani, Angela ; Troldborg, Anne ; Van Vollenhoven, Ronald ; Wenzel, Jörg ; Bertsias, George ; Boumpas, Dimitrios T. / 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. In: Annals of the Rheumatic Diseases. 2019 ; Vol. 78, No. 6. pp. 736-745.
@article{c0eedaa3201748a38607025be7ff8e06,
title = "2019 update of the EULAR recommendations for the management of systemic lupus erythematosus",
abstract = "Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of GC. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab (RTX) may be considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion.",
keywords = "lupus nephritis, systemic lupus erythematosus, treatment",
author = "Antonis Fanouriakis and Myrto Kostopoulou and Alessia Alunno and Martin Aringer and Ingeborg Bajema and Boletis, {John N.} and Ricard Cervera and Andrea Doria and Caroline Gordon and Marcello Govoni and Fr{\'e}d{\'e}ric Houssiau and David Jayne and Marios Kouloumas and Annegret Kuhn and Larsen, {Janni L.} and Kirsten Lerstr{\o}m and Gabriella Moroni and Marta Mosca and Matthias Schneider and Smolen, {Josef S.} and Elisabet Svenungsson and Vladimir Tesar and Angela Tincani and Anne Troldborg and {Van Vollenhoven}, Ronald and J{\"o}rg Wenzel and George Bertsias and Boumpas, {Dimitrios T.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/annrheumdis-2019-215089",
language = "English",
volume = "78",
pages = "736--745",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

AU - Fanouriakis, Antonis

AU - Kostopoulou, Myrto

AU - Alunno, Alessia

AU - Aringer, Martin

AU - Bajema, Ingeborg

AU - Boletis, John N.

AU - Cervera, Ricard

AU - Doria, Andrea

AU - Gordon, Caroline

AU - Govoni, Marcello

AU - Houssiau, Frédéric

AU - Jayne, David

AU - Kouloumas, Marios

AU - Kuhn, Annegret

AU - Larsen, Janni L.

AU - Lerstrøm, Kirsten

AU - Moroni, Gabriella

AU - Mosca, Marta

AU - Schneider, Matthias

AU - Smolen, Josef S.

AU - Svenungsson, Elisabet

AU - Tesar, Vladimir

AU - Tincani, Angela

AU - Troldborg, Anne

AU - Van Vollenhoven, Ronald

AU - Wenzel, Jörg

AU - Bertsias, George

AU - Boumpas, Dimitrios T.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of GC. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab (RTX) may be considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion.

AB - Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of GC. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab (RTX) may be considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion.

KW - lupus nephritis

KW - systemic lupus erythematosus

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85063719926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063719926&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2019-215089

DO - 10.1136/annrheumdis-2019-215089

M3 - Article

VL - 78

SP - 736

EP - 745

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 6

ER -